China ADC Development and Innovation Landscape
China has fundamentally reshaped the global ADC landscape — no longer merely a manufacturing base, but an increasingly dominant force in ADC discovery, development, and deal-making. As of November 2025, China-based developers account for approximately 25% of all ADC assets across traditional, bispecific, and dual-payload modalities, and an even more commanding share of next-generation innovation.
The country's trajectory is striking. In traditional ADCs, China is firmly established, holding stakes in 50% (9 out of 18) of all globally approved ADCs. In next-generation modalities, China's participation is even more pronounced: 54% of all bispecific ADCs and 38% of all dual-payload ADCs globally involve Chinese developers. The two only clinical-stage dual-payload ADCs worldwide — KH815 and IBI3020 — are both led by Chinese companies.
This analysis provides a comprehensive overview of China's expanding role across ADC modalities, the deal landscape and the competitive dynamics shaping the sector as it moves into 2026.
ADC Pipeline Overview: Growth by Modality
Global ADC development has accelerated dramatically over the past five years. First-disclosure entries rose from 406 in 2021 to a peak of 795 in 2024, with 522 new entries recorded as of October 2025. Traditional ADCs continue to dominate overall activity, but since 2023, bispecific and dual-payload ADCs have emerged as the primary growth drivers — and it is Chinese developers who are largely propelling them forward.
Between 2023 and October 2025, China-linked traditional ADCs accounted for approximately 34% of global disclosures. For bispecific and dual-payload modalities, China-linked assets reached 59% and 39% of global disclosures, respectively — underscoring the degree to which Chinese developers are shaping the next generation of ADC innovation.
Traditional ADC: Targets & Payload Mechanisms
Top Targets
Within traditional ADC programs involving China-based companies, HER2 and TROP-2 remain the dominant targets — closely aligned with global development patterns. However, Chinese developers demonstrate particular strategic depth in pursuing targets that receive comparatively limited attention from Western developers:
- CLDN18.2: All CLDN18.2-targeting ADCs that have progressed to Phase 3 involve Chinese developers, often through cross-border collaborations. Arcotatug tavatecan (Innovent), partnered with Takeda in a landmark $11.4 billion deal, exemplifies this dynamic.
- CDH17: The majority of CDH17-targeting ADCs presented at AACR 2025 originate from Chinese developers, including Lepu Biopharma's MRG007 and LaNova Medicines' LM-350.
- B7-H3 (CD276): A rapidly growing target with strong China's participation, reflecting the broader pattern of China-led development in underserved oncology targets.
Top Payload Mechanisms
China's top five ADC payload mechanisms broadly align with global development priorities, but with significant market share:
China represents 64% of all active topo I-based ADCs in the clinic and 57% of tubulin-based ADCs — a dominant clinical presence that reflects years of investment in these established payload classes.
A notable emerging development: the world's only two RNA Polymerase II inhibitor ADCs — HDP-102 and Pamlectabart tismanitin — are co-developed by Huadong Medicine (China) and Heidelberg Pharma (Germany). Pamlectabart tismanitin recently received FDA Fast Track Designation for multiple myeloma, with Phase II development planned in China for 2026.
Bispecific ADC
Bispecific ADCs represent the most rapidly growing next-generation modality, and China is its undisputed leader. Among the top five bispecific ADC target pairs involving Chinese developers, China-based developers hold near-exclusive positions in the two most active categories:
Key Bispecific ADC Highlights
- JSKN-003 (Jiangsu Hengrui Medicine): Advanced to Phase 3 with promising efficacy data in colorectal cancer presented at ESMO 2025, highlighting the expanding potential of refined HER2 targeting beyond traditional indications.
- Izalontamab brengitecan (BL-B01D1): The only Phase 3 EGFR × HER-3 ADC, developed by Sichuan Biokin. Recently received NMPA Breakthrough Therapy Designation for metastatic urothelial carcinoma and EGFR-mutated NSCLC. This asset alone is the subject of 44 active clinical trials — a remarkable development density.
While c-MET × EGFR has the highest number of bispecific ADC candidates, all assets remain in early development. In contrast, HER-2 × HER-2 has only three candidates, yet two have advanced to Phase 3 — reflecting the strategic efficiency of targeting well-characterized pathways with a bispecific approach.
Dual-Payload ADC
Dual-payload ADCs represent the most technically ambitious modality, combining two distinct payload mechanisms within a single construct to address tumor heterogeneity and resistance mechanisms. China is uniquely positioned in this space:
- KH815: The world's first and only dual-payload ADC to enter clinical development for advanced solid tumors, marking an important clinical proof-of-concept for the modality.
- IBI3020: The second clinical-stage dual-payload ADC globally.
The leading dual-payload combinations involving China-based developers are:
Phrontline Biopharma specializes in dual-payload bispecific ADCs for solid tumors, and its recent partnership with Samsung Bioepis (Korea) highlights growing global interest in complex ADC architectures.
Shanghai Affinity Biopharmaceutical pursues its proprietary Tumor MicroEnvironment Activated (TMEA) platform, enabling selective payload release based on tumor-specific protease activity and metabolic conditions — a differentiated approach to payload combination engineering.
Deals & Investment
The volume and scale of ADC licensing and co-development deals involving Chinese developers have reached new heights in 2025, reflecting the strategic importance of China-based innovation in global pharma ADC portfolios.
Selected Major Deals
The cumulative potential deal value of new ADC transactions involving China-based developers exceeds $24 billion, with Takeda–Innovent ($11.4 billion) and BioNTech–MediLink ($1.8 billion) standing out as the landmark transactions of the year. Notably, both involve Japan–China and Germany–China cross-border partnerships, respectively, reflecting the global reach of Chinese ADC innovation.
Beyond licensing, a new trend is emerging: ADC platform partnerships, as exemplified by the Samsung Bioepis–Phrontline Biopharma deal for dual-payload bispecific ADC technology. This suggests that China's ADC capabilities are increasingly being recognized not just at the individual asset level, but at the platform and technology level.
Competitive Landscape: Top Chinese ADC Developers
The Chinese ADC competitive landscape spans multinational pharmas with China operations, domestic champions, and emerging biotechs with platform technologies. The following provides a snapshot of key players:
Regulatory Dynamics: NMPA's Evolving Role
China's NMPA has undergone significant regulatory modernization, making it an increasingly attractive jurisdiction for ADC development and a credible alternative to FDA or EMA regulatory pathways for global developers.
Key Regulatory Developments
- IND Review Timeline: NMPA has shortened IND (Investigational New Drug) application review timelines from 60 working days to 30 working days — a major improvement in development velocity.
- BTD (Breakthrough Therapy Designation): NMPA BTD provides an accelerated regulatory pathway for ADCs addressing unmet medical needs. Izalontamab brengitecan (BL-B01D1) received NMPA BTD for metastatic urothelial carcinoma and EGFR-mutated NSCLC — illustrating how China-based assets can leverage dual regulatory strategies (NMPA + FDA designations simultaneously).
- Regulatory Standard Alignment: NMPA has progressively aligned ADC regulatory standards with FDA and EMA requirements, building confidence among international pharma partners and enabling cross-border regulatory strategies.
- Global Regulatory Strategy: China-based ADC developers increasingly pursue simultaneous regulatory filings in China (NMPA), the US (FDA), Europe (EMA), and Japan (PMDA), leveraging cross-regional data packages to accelerate global approval timelines.
2026 Outlook: Five Structural Trends
Based on current trajectory, Beacon ADC identifies five structural trends that will define China's ADC sector through 2026:
1. Continued Bispecific & Dual-Payload Momentum
The concentration of China-based development in bispecific ADCs (54%) and dual-payload ADCs (38%) will continue to intensify. As assets in these modalities advance through Phase 1–2, expect increasing Phase 3 readouts and a wave of partnering activity from global pharmas seeking access to validated next-generation ADC platforms.
2. Cross-Border Deal Volume to Remain Elevated
With $24B+ in potential new deal value identified across the pipeline, 2026 is likely to see continued major cross-border ADC licensing and co-development transactions. Pharma majors (Takeda, BioNTech, Roche/Genentech, GSK, AbbVie) have signaled strong appetite for China-originated ADC innovation. Deal structures may evolve from pure out-licensing toward equity investments, JV structures, and platform-level partnerships.
3. Clinical Trial Concentration to Deepen
China's 54% AAGR in ADC trials (vs. 34% globally) and its >50% share of total global ADC trials since 2023 point to a structural shift. As global pharma increasingly runs multi-regional clinical trials, China will serve as the primary enrollment engine — particularly for Phase 3 combination studies, where 75% of trials are already China-based.
4. Novel Payload Classes to Advance into Clinic
China's emerging presence in RNA Polymerase II inhibitor ADCs (co-developed with Heidelberg Pharma) and the expanding dual-payload landscape signal that Chinese developers are moving beyond established topo I and tubulin payloads. Pamlectabart tisagenlin's FDA Fast Track Designation and planned China Phase II for 2026 represent the leading edge of this trend.
5. Manufacturing & CDMO Capacity as a Strategic Asset
As multiple China-originated ADCs advance toward commercial approval, China's integrated ADC CDMO infrastructure — spanning antibody manufacturing, linker-payload conjugation, fill-finish, and quality systems — will become an increasingly strategic asset for global partners seeking reliable, scalable supply chains.
Explore ChemExpress's integrated ADC platform across payload-linker development, conjugation, drug substance process development, manufacturing, and analytical quality control.
ChemExpress's XDC CDMO Platform: Enabling the Next Phase of China ADC Innovation
As China-originated ADC candidates advance from preclinical into clinical and commercial stages, the demand for high-quality, integrated XDC (Antibody-Drug Conjugate) CDMO services is accelerating. ChemExpress has built a comprehensive platform spanning the full ADC value chain — from proprietary cytotoxic payloads and linkers to large-scale conjugation and fill-finish.
Core platform capabilities:
- 150+ GMP-certified cytotoxic payloads (exatecan mesylate, MMAE, DM1, MMAF, Duocarmycin, PBD dimers)
- 500+ linker intermediates and proprietary cleavable/non-cleavable linker platforms
- 2,000+ ADC synthesis records across multiple modalities
- 16 FDA DMF filings — strong regulatory track record supporting US and global submissions
- 6 BLA-enabling projects and 1 commercial-stage ADC product — demonstrated manufacturing to market capability
- FDA zero 483 observations across all GMP audits; EU QP GMP audit compliance
- 5 OEB5-compliant high-potency lines for handling ultra-potent payloads
- 1,500 kg/year ADC drug substance manufacturing capacity; 5M vials/year fill-finish capacity
- Proprietary optimized synthesis route for Exatecan Mesylate — simplified process, reduced cost of goods
The convergence of China-based innovation and world-class manufacturing standards positions partners like ChemExpress as critical enablers of the next phase of global ADC development — from first-in-human studies through commercial launch at global scale.